Azacitidine maintenance after allogeneic hematopoietic cell transplantation for MDS and AML

Firas El Chaer; Uma Borate; Rémy Duléry; Shernan G. Holtan; Arjun Datt Law; Lori Muffly; Samah Nassereddine; Rory M. Shallis; Kate Stringaris; Justin Taylor; Steven M. Devine; Mohamad Mohty; Christopher S. Hourigan

doi:10.1182/bloodadvances.2020003839

Azacitidine maintenance after allogeneic hematopoietic cell transplantation for MDS and AML

Firas El Chaer, Uma Borate, Rémy Duléry, Shernan G. Holtan, Arjun Datt Law, Lori Muffly, Samah Nassereddine, Rory M. Shallis, Kate Stringaris, Justin Taylor, Steven M. Devine, Mohamad Mohty, Christopher S. Hourigan

Medicine - Hematology, Oncology, Transplant

Research output: Contribution to journal › Comment/debate › peer-review

9 Scopus citations

Original language	English (US)
Pages (from-to)	1757-1759
Number of pages	3
Journal	Blood Advances
Volume	5
Issue number	6
DOIs	https://doi.org/10.1182/bloodadvances.2020003839
State	Published - Mar 23 2021

Bibliographical note

Funding Information:
Conflict-of-interest disclosure: U.B. has served as a consultant for Genentech and Bristol Myers Squibb and has research funding from Astellas. S.G.H. has served as a consultant for Incyte, Bristol Myers Squibb, and Generon. L.M. has research funding from Jasper, Adaptive, Astellas, and Servier and has served as a consultant for Pfizer and Amgen. The remaining authors declare no competing financial interests.

Funding Information:
Acknowledgments: This work was supported in part by the Intramural Research Program of the National Heart, Lung, and Blood Institute, National Institutes of Health (grant 1ZIAHL006163).

Access

10.1182/bloodadvances.2020003839

OpenUrl availability

Full text

Cite this

@article{2838f569c7f7470f9541d8c7315f1edf,

title = "Azacitidine maintenance after allogeneic hematopoietic cell transplantation for MDS and AML",

author = "Chaer, {Firas El} and Uma Borate and R{\'e}my Dul{\'e}ry and Holtan, {Shernan G.} and Law, {Arjun Datt} and Lori Muffly and Samah Nassereddine and Shallis, {Rory M.} and Kate Stringaris and Justin Taylor and Devine, {Steven M.} and Mohamad Mohty and Hourigan, {Christopher S.}",

note = "Funding Information: Conflict-of-interest disclosure: U.B. has served as a consultant for Genentech and Bristol Myers Squibb and has research funding from Astellas. S.G.H. has served as a consultant for Incyte, Bristol Myers Squibb, and Generon. L.M. has research funding from Jasper, Adaptive, Astellas, and Servier and has served as a consultant for Pfizer and Amgen. The remaining authors declare no competing financial interests. Funding Information: Acknowledgments: This work was supported in part by the Intramural Research Program of the National Heart, Lung, and Blood Institute, National Institutes of Health (grant 1ZIAHL006163).",

year = "2021",

month = mar,

day = "23",

doi = "10.1182/bloodadvances.2020003839",

language = "English (US)",

volume = "5",

pages = "1757--1759",

journal = "Blood Advances",

issn = "2473-9529",

publisher = "American Society of Hematology",

number = "6",

}

TY - JOUR

T1 - Azacitidine maintenance after allogeneic hematopoietic cell transplantation for MDS and AML

AU - Chaer, Firas El

AU - Borate, Uma

AU - Duléry, Rémy

AU - Holtan, Shernan G.

AU - Law, Arjun Datt

AU - Muffly, Lori

AU - Nassereddine, Samah

AU - Shallis, Rory M.

AU - Stringaris, Kate

AU - Taylor, Justin

AU - Devine, Steven M.

AU - Mohty, Mohamad

AU - Hourigan, Christopher S.

N1 - Funding Information: Conflict-of-interest disclosure: U.B. has served as a consultant for Genentech and Bristol Myers Squibb and has research funding from Astellas. S.G.H. has served as a consultant for Incyte, Bristol Myers Squibb, and Generon. L.M. has research funding from Jasper, Adaptive, Astellas, and Servier and has served as a consultant for Pfizer and Amgen. The remaining authors declare no competing financial interests. Funding Information: Acknowledgments: This work was supported in part by the Intramural Research Program of the National Heart, Lung, and Blood Institute, National Institutes of Health (grant 1ZIAHL006163).

PY - 2021/3/23

Y1 - 2021/3/23

UR - http://www.scopus.com/inward/record.url?scp=85103305080&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85103305080&partnerID=8YFLogxK

U2 - 10.1182/bloodadvances.2020003839

DO - 10.1182/bloodadvances.2020003839

M3 - Comment/debate

C2 - 33755090

AN - SCOPUS:85103305080

SN - 2473-9529

VL - 5

SP - 1757

EP - 1759

JO - Blood Advances

JF - Blood Advances

IS - 6

ER -

Azacitidine maintenance after allogeneic hematopoietic cell transplantation for MDS and AML

Bibliographical note

Access

OpenUrl availability

Other files and links

Cite this